口服的icotrokinra用于成人和青少年的斑块性牛皮
Erum Habib1,2, Ursula Abu Nahla3, Muhammad Haris4
1Department of Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan.
Annals of medicine and surgery (2012)
|January 7, 2026
概括
口服的icotrokinra为中度至严重的斑块性牛皮提供了一种新的,方便的治疗方法. 这种选择性互白素-23受体抗剂显示出显著的症状缓解和有效的患者安全概况.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斑块性牛皮是一种慢性炎症性皮肤疾病,影响生活质量.
- 目前的治疗方法包括全身疗法和生物药物,往往有管理方面的挑战.
研究的目的:
- 评估口服伊科特罗金拉在中度至重度斑块性牛皮的疗效和安全性.
- 评估icotrokinra作为注射性牛皮治疗的方便替代品.
主要方法:
- 临床试验涉及中度至重度斑块性牛皮的成年和青少年患者.
- 评估牛皮区域和严重性指数 (PASI) 评分和症状缓解.
- 监测不良事件和安全概况.
主要成果:
- 在PASI得分显著降低和显著的症状缓解.
- 在以前没有接受过治疗的患者和患有广泛疾病的患者中有效.
- 具有轻微,短暂的副作用的有利安全概况;没有报告严重不良事件.
结论:
- 口服的icotrokinra显示出显著的疗效和对斑块性牛皮的良好的安全性.
- 与注射疗法相比,它的口服提供了更好的方便性和坚持性.
- 伊科特罗金拉为治疗牛皮和改善患者生活质量提供了一个有前途的新疗法.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Drugs for Treatment of Ulcerative Colitis in IBD
449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425


